1
|
D'elia Y, Whitfield T, Schlosser M, Lutz A, Barnhofer T, Chételat G, Marchant NL, Gonneaud J, Klimecki O. Impact of mindfulness-based and health self-management interventions on mindfulness, self-compassion, and physical activity in older adults with subjective cognitive decline: A secondary analysis of the SCD-Well randomized controlled trial. ALZHEIMER'S & DEMENTIA (AMSTERDAM, NETHERLANDS) 2024; 16:e12558. [PMID: 38440222 PMCID: PMC10910278 DOI: 10.1002/dad2.12558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Revised: 11/01/2023] [Accepted: 01/24/2024] [Indexed: 03/06/2024]
Abstract
INTRODUCTION Older adults experiencing subjective cognitive decline (SCD) have a higher risk of dementia. Reducing this risk through behavioral interventions, which can increase emotional well-being (mindfulness and compassion) and physical activity, is crucial in SCD. METHODS SCD-Well is a multicenter, observer-blind, randomized, controlled, superiority trial. Three hundred forty-seven participants (mean [standard deviation] age: 72.7 [6.9] years; 64.6% women) were recruited from memory clinics in four European sites to assess the impact of an 8-week caring mindfulness-based approach for seniors (CMBAS) and a health self-management program (HSMP) on mindfulness, self-compassion, and physical activity. RESULTS CMBAS showed a significant within-group increase in self-compassion from baseline to post-intervention and both a within- and between-group increase to follow-up visit (24 weeks). HSMP showed a significant within- and between-group increase in physical activity from baseline to post-intervention and to follow-up visit. DISCUSSION Non-pharmacological interventions can differentially promote modifiable factors linked to healthy aging in older adults with SCD.
Collapse
Affiliation(s)
- Ylenia D'elia
- Department of Clinical Psychology and Behavioral NeuroscienceUniversity of Technology DresdenDresdenGermany
| | - Tim Whitfield
- Division of Psychiatry Faculty of Brain SciencesUniversity College LondonLondonUK
| | - Marco Schlosser
- Division of Psychiatry Faculty of Brain SciencesUniversity College LondonLondonUK
- Department of PsychologyFaculty of Psychology and Educational SciencesUniversity of GenevaGenevaSwitzerland
| | - Antoine Lutz
- Lyon Neuroscience Research Center, Inserm U1028, CNRS UMR5292, Lyon 1 UniversityLyonFrance
| | | | - Gaël Chételat
- Normandie Univ, UNICAEN, INSERM, U1237, PhIND “Physiopathology and Imaging of Neurological Disorders,” NeuroPresage Team, CyceronCaenFrance
| | - Natalie L. Marchant
- Division of Psychiatry Faculty of Brain SciencesUniversity College LondonLondonUK
| | - Julie Gonneaud
- Normandie Univ, UNICAEN, INSERM, U1237, PhIND “Physiopathology and Imaging of Neurological Disorders,” NeuroPresage Team, CyceronCaenFrance
| | - Olga Klimecki
- Department of PsychologyFaculty of Psychology and Educational SciencesUniversity of GenevaGenevaSwitzerland
- Department of Developmental PsychologyUniversity of JenaJenaGermany
| |
Collapse
|
2
|
Schlosser M, Demnitz-King H, Barnhofer T, Collette F, Gonneaud J, Chételat G, Jessen F, Kliegel M, Klimecki OM, Lutz A, Marchant NL. Effects of a mindfulness-based intervention and a health self-management programme on psychological well-being in older adults with subjective cognitive decline: Secondary analyses from the SCD-Well randomised clinical trial. PLoS One 2023; 18:e0295175. [PMID: 38100477 PMCID: PMC10723715 DOI: 10.1371/journal.pone.0295175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2023] [Accepted: 11/07/2023] [Indexed: 12/17/2023] Open
Abstract
OBJECTIVES Older adults with subjective cognitive decline (SCD) recruited from memory clinics have an increased risk of developing dementia and regularly experience reduced psychological well-being related to memory concerns and fear of dementia. Research on improving well-being in SCD is limited and lacks non-pharmacological approaches. We investigated whether mindfulness-based and health education interventions can enhance well-being in SCD. METHODS The SCD-Well trial (ClinicalTrials.gov: NCT03005652) randomised 147 older adults with SCD to an 8-week caring mindfulness-based approach for seniors (CMBAS) or an active comparator (health self-management programme [HSMP]). Well-being was assessed at baseline, post-intervention, and 6-month post-randomisation using the Psychological Well-being Scale (PWBS), the World Health Organisation's Quality of Life (QoL) Assessment psychological subscale, and composites capturing meditation-based well-being dimensions of awareness, connection, and insight. Mixed effects models were used to assess between- and within-group differences in change. RESULTS CMBAS was superior to HSMP on changes in connection at post-intervention. Within both groups, PWBS total scores, psychological QoL, and composite scores did not increase. Exploratory analyses indicated increases in PWBS autonomy at post-intervention in both groups. CONCLUSION Two non-pharmacological interventions were associated with only limited effects on psychological well-being in SCD. Longer intervention studies with waitlist/retest control groups are needed to assess if our findings reflect intervention brevity and/or minimal base rate changes in well-being.
Collapse
Affiliation(s)
- Marco Schlosser
- Department of Psychology, Faculty of Psychology and Educational Sciences, University of Geneva, Geneva, Switzerland
- Division of Psychiatry, Faculty of Brain Sciences, University College London, London, United Kingdom
| | - Harriet Demnitz-King
- Division of Psychiatry, Faculty of Brain Sciences, University College London, London, United Kingdom
| | | | - Fabienne Collette
- GIGA-CRC In Vivo Imaging, University of Liège, Liège, Belgium
- Psychology and Neuroscience of Cognition Research Unit, Faculty of Psychology and Educational Sciences, University of Liège, Liège, Belgium
| | - Julie Gonneaud
- Normandie Univ, UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging of Neurological Disorders", Institut Blood and Brain @ Caen-Normandie, Cyceron, Caen, France
| | - Gaël Chételat
- Normandie Univ, UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging of Neurological Disorders", Institut Blood and Brain @ Caen-Normandie, Cyceron, Caen, France
| | - Frank Jessen
- Department of Psychiatry, Medical Faculty, University of Cologne, Cologne, Germany
- German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
- Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany
| | - Matthias Kliegel
- Department of Psychology, Faculty of Psychology and Educational Sciences, University of Geneva, Geneva, Switzerland
| | - Olga M. Klimecki
- Swiss Center for Affective Sciences, University of Geneva, Geneva, Switzerland
- Clinical Psychology and Behavioral Neuroscience, Faculty of Psychology, Technische Universität Dresden, Dresden, Germany
| | - Antoine Lutz
- Eduwell team, Lyon Neuroscience Research Center Inserm U1028, CNRS UMR5292, Lyon 1 University, Lyon, France
| | - Natalie L. Marchant
- Division of Psychiatry, Faculty of Brain Sciences, University College London, London, United Kingdom
| | | |
Collapse
|
3
|
Teixeira-Santos AC, Gomes L, Pereira DR, Ribeiro F, Silva-Fernandes A, Federspiel C, Steinmetz JP, Leist AK. The MEDITAGING study: protocol of a two-armed randomized controlled study to compare the effects of the mindfulness-based stress reduction program against a health promotion program in older migrants in Luxembourg. BMC Public Health 2023; 23:2470. [PMID: 38082350 PMCID: PMC10714656 DOI: 10.1186/s12889-023-17387-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Accepted: 11/30/2023] [Indexed: 12/18/2023] Open
Abstract
BACKGROUND Migration is a phenomenon worldwide, with older migrants, particularly those with fewer socioeconomic resources, having an increased risk of developing adverse cognitive and health outcomes and social isolation. Therefore, it is of utmost importance to validate interventions that promote healthy aging in this population. Previous studies have shown a positive impact of mindfulness based-stress reduction (MBSR) on outcomes such as cognition and sleep. However, only a few studies verified its potential in older adults, especially with vulnerable populations such as migrants. This article presents the protocol of the MEDITAGING study, which is the first to investigate the MBSR effects in migrants aged ≥55 in comparison to a health promotion program. METHODS MEDITAGING is a two-arm randomized, double-blinded, controlled study, which will include older Portuguese-speaking migrants (n = 90). Participants are randomized to the MBSR or a health promotion program. Both interventions are conducted in groups over a total of 8 weeks, incorporating weekly meetings, an additional 4-hour class, and extra at-home tasks. The health promotion program has the same structure as the MBSR but comprises different activities related to dementia prevention, healthy habits, cognitive stimulation, sleeping, nutrition, watercolor painting, and physical activity. The assessment of executive functioning, physiological stress measures, self-reported questionnaires, and qualitative interviews are conducted at baseline, after 8 weeks (post-intervention), and at a follow-up session (from one to 3 months thereafter). Analyzes will be conducted using a modified intention-to-treat approach (all participants with at least 3 days of participation in the group-sessions and one post-intervention observation). DISCUSSION This study will test effects of a mindfulness-based intervention against an active control condition in older adult migrants, which few studies have addressed. TRIAL REGISTRATION ClinicalTrials.gov NCT05615337 (date of registration: 27 September 2022; date of record verification: 14 November 2022).
Collapse
Affiliation(s)
- Ana C Teixeira-Santos
- Department of Social Sciences, Institute for Research on Socio-Economic Inequality, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
| | - Leandro Gomes
- Interdisciplinary Postgraduate Program in Human Sciences, State University of Amazonas PPGICH/UEA, Manaus, Brazil
- NAURBE Group - Cities, Popular Cultures and Heritage, Federal University of Amazonas - Postgraduate Program in Social Anthropology, Manaus, Brazil
| | - Diana R Pereira
- Human Cognition Laboratory - CIPsi, School of Psychology, University of Minho, Braga, Portugal
| | - Fabiana Ribeiro
- Department of Social Sciences, Institute for Research on Socio-Economic Inequality, University of Luxembourg, Esch-sur-Alzette, Luxembourg
| | - Anabela Silva-Fernandes
- Psychological Neuroscience Laboratory, CIPsi, School of Psychology, University of Minho, Braga, Portugal
| | | | | | - Anja K Leist
- Department of Social Sciences, Institute for Research on Socio-Economic Inequality, University of Luxembourg, Esch-sur-Alzette, Luxembourg
| |
Collapse
|
4
|
Zaidi SZH, Mithila MV, Mavathur RN, Nagarathna R, Thulasi A, Ramsahaye AY, Naresh K, Shukla HA. Yoga Module Development and Validation for Sickle Cell Disease. Int J Yoga 2023; 16:219-225. [PMID: 38463648 PMCID: PMC10919411 DOI: 10.4103/ijoy.ijoy_169_23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Revised: 11/02/2023] [Accepted: 11/03/2023] [Indexed: 03/12/2024] Open
Abstract
Introduction Sickle cell disease (SCD) is a genetic blood disorder that affects the shape and function of red blood cells (RBCs), which can lead to several health problems affecting the quality of life. SCD can be treated with certain expensive treatments such as RBC transfusion, hydroxyurea, stem cell transplantation, gene therapy, or bone marrow transplant. However, some of the most common symptoms such as pain, anxiety, and stress can also be alleviated with alternative therapies like yoga. In light of this, there is a need for the development of a specific yoga module (YM) for SCD that can complement the current therapies. Objective To develop and validate a YM for SCD. Methodology Concise literature reports on yoga practices used for varied symptoms/comorbidities associated with SCD were compiled and presented to focus groups. Based on the presented report and personal experience, the focus group created a preliminary version of the module. The preliminary module was further refined based on content validity ratio (CVR) following module validation by 33 yoga experts. Results One hour ten minutes module developed by the focus group had in total 27 practices including, loosening exercises, asanas, pranayama, relaxation techniques, and meditation. After validation by the experts, 21 practices with a CVR ≥ 0.33 were retained. The predominant reason for excluding 12 practices was intensity, which may have some adverse effect on sickle cell comorbidities. Conclusion The module developed is the first validated module for SCD.
Collapse
Affiliation(s)
- Syed Zaeem Haider Zaidi
- Division of Yoga and Life Sciences, Swami Vivekananda Yoga Anusandhana Samsthana (S-VYASA), Bangalore, Karnataka, India
| | - M V Mithila
- Division of Yoga and Life Sciences, Swami Vivekananda Yoga Anusandhana Samsthana (S-VYASA), Bangalore, Karnataka, India
| | - Ramesh Nanjundaiah Mavathur
- Division of Yoga and Life Sciences, Swami Vivekananda Yoga Anusandhana Samsthana (S-VYASA), Bangalore, Karnataka, India
| | - R Nagarathna
- Medical Director of Arogyadhama, Prashanti Kuteeram, Division of Yoga and Life Sciences, Swami Vivekananda Yoga Anusandhana Samsthana (S-VYASA), Bangalore, Karnataka, India
| | - Arun Thulasi
- Division of Yoga and Humanities, Swami Vivekananda Yoga Anusandhana Samsthana (S-VYASA), Bangalore, Karnataka, India
| | - Atmika Y Ramsahaye
- Division of Yoga and Humanities, Swami Vivekananda Yoga Anusandhana Samsthana (S-VYASA), Bangalore, Karnataka, India
| | - Katla Naresh
- Division of Yoga and Humanities, Swami Vivekananda Yoga Anusandhana Samsthana (S-VYASA), Bangalore, Karnataka, India
| | - Himanshu A Shukla
- Division of Yoga and Life Sciences, Swami Vivekananda Yoga Anusandhana Samsthana (S-VYASA), Bangalore, Karnataka, India
| |
Collapse
|
5
|
Effects of Mindfulness-Based Interventions (MBIs) in Patients with Early-Stage Alzheimer’s Disease: A Pilot Study. Brain Sci 2023; 13:brainsci13030484. [PMID: 36979294 PMCID: PMC10046197 DOI: 10.3390/brainsci13030484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Revised: 03/06/2023] [Accepted: 03/08/2023] [Indexed: 03/16/2023] Open
Abstract
Bachground In this study, we hypothesize that mindfulness-based interventions (MBIs) may improve well-being and the related outcomes in Alzheimer’s dementia patients (AD-P) at an early stage. MBIs consist of the practice of consciously observing the psychic contents in the present moment (thoughts, sensations, feelings, and other events). This attention allows one to become aware of the psychic contents and integrate them, thus favoring the quality of life and an increase in the mood of practitioners. Methods The randomized controlled study enrolled 22 AD-P at an early stage (age ≥ 60 years) treated with MBIs and 22 patients without treatment (six months of MBI training). Tests (T0–T1 six months): Mini-Mental State Examination (MMPI); Spiritual Well-Being (SWB); Beck Depression Inventory (BDI); SF36. Test-Caregiver: Everyday Cognition scales (ECOG). Results AD-P with mindfulness: Improvement of ECOG (p = 0.026), quality of life (p < 0.001), spiritual well-being (p < 0.001); decrease in depression BDI (p < 0.001). The MMSE remains unchanged. The control group of untreated patients showed a significant worsening in all these dimensions. Conclusions MBI training is effective in increasing quality of life and preventing worsening in patients with early-stage Alzheimer’s dementia.
Collapse
|
6
|
Demnitz-King H, Gonneaud J, Klimecki OM, Chocat A, Collette F, Dautricourt S, Jessen F, Krolak-Salmon P, Lutz A, Morse RM, Molinuevo JL, Poisnel G, Touron E, Wirth M, Walker Z, Chételat G, Marchant NL. Association of Self-reflection With Cognition and Brain Health in Cognitively Unimpaired Older Adults. Neurology 2022; 99:e1422-e1431. [PMID: 35853750 DOI: 10.1212/wnl.0000000000200951] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2021] [Accepted: 05/24/2022] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND AND OBJECTIVES Self-reflection (the active evaluation of ones thoughts, feelings, and behaviors) can confer protection against adverse health outcomes. Its effect on markers sensitive to Alzheimer disease (AD), however, is unknown. The primary objective of this cross-sectional study was to examine the association between self-reflection and AD-sensitive markers. METHODS This study used baseline data from cognitively unimpaired older adults enrolled in the Age-Well clinical trial and older adults with subjective cognitive decline from the SCD-Well clinical trial. In both cohorts, self-reflection was measured via the reflective pondering subscale of the Rumination Response Scale, global cognition assessed via the Preclinical Alzheimer's Cognitive Composite 5, and a modified late-life Lifestyle-for-Brain-Health (LIBRA) index computed to assess health and lifestyle factors. In Age-Well, glucose metabolism and amyloid deposition were quantified in AD-sensitive gray matter regions via fluorodeoxyglucose- and AV45-PET scans, respectively. Associations between self-reflection and AD-sensitive markers (global cognition, glucose metabolism, and amyloid deposition) were assessed via unadjusted and adjusted regressions. Furthermore, we explored whether associations were independent of health and lifestyle factors. To control for multiple comparisons in Age-Well, false discovery rate-corrected p values (p FDR) are reported. RESULTS A total of 134 (mean age 69.3 ± 3.8 years, 61.9% women) Age-Well and 125 (mean age 72.6 ± 6.9 years, 65.6% women) SCD-Well participants were included. Across unadjusted and adjusted analyses, self-reflection was associated with better global cognition in both cohorts (Age-Well: adjusted-β = 0.22, 95% CI 0.05-0.40, p FDR = 0.041; SCD-Well: adjusted-β = 0.18, 95% CI 0.03-0.33, p = 0.023) and with higher glucose metabolism in Age-Well after adjustment for all covariates (adjusted-β = 0.29, 95% CI 0.03-0.55, p FDR = 0.041). Associations remained following additional adjustment for LIBRA but did not survive false discovery rate (FDR) correction. Self-reflection was not associated with amyloid deposition (adjusted-β = 0.13, 95% CI -0.07 to 0.34, p FDR = 0.189). DISCUSSION Self-reflection was associated with better global cognition in 2 independent cohorts and with higher glucose metabolism after adjustment for covariates. There was weak evidence that relationships were independent from health and lifestyle behaviors. Longitudinal and experimental studies are warranted to elucidate whether self-reflection helps preserve cognition and glucose metabolism or whether reduced capacity to self-reflect is a harbinger of cognitive decline and glucose hypometabolism. TRIAL REGISTRATION INFORMATION Age-Well: NCT02977819; SCD-Well: NCT03005652.
Collapse
Affiliation(s)
- Harriet Demnitz-King
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Julie Gonneaud
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Olga M Klimecki
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Anne Chocat
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Fabienne Collette
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Sophie Dautricourt
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Frank Jessen
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Pierre Krolak-Salmon
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Antoine Lutz
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Rachel M Morse
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - José Luis Molinuevo
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Géraldine Poisnel
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Edelweiss Touron
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Miranka Wirth
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Zuzana Walker
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Gaël Chételat
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Natalie L Marchant
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden.
| | | |
Collapse
|
7
|
Whitfield T, Demnitz-King H, Schlosser M, Barnhofer T, Frison E, Coll-Padros N, Dautricourt S, Requier F, Delarue M, Gonneaud J, Klimecki OM, Lutz A, Paly L, Salmon E, Schild AK, Walker Z, Jessen F, Chételat G, Collette F, Wirth M, Marchant NL, Michon A, Sanchez-Valle R, Schwars C, Lai C, Coueron R, Arenaza-Urquijo EM, Poisnel G, Delphin-Combe F, Asselineau J, Krolak-Salmon P, Molinuevo JL, Allais F, Bachelet R, Belleoud V, Benson C, Bosch B, Casanova MP, Espérou H, Goldet K, Hamdidouche I, Leon M, Meiberth D, Mueller H, Mueller T, Ourry V, Reyrolle L, Salinero A, Sannemann L, Satgunasingam Y, Steinhauser H, Vuilleumier P, Wallet C, Wingrove J. Effects of a mindfulness-based versus a health self-management intervention on objective cognitive performance in older adults with subjective cognitive decline (SCD): a secondary analysis of the SCD-Well randomized controlled trial. Alzheimers Res Ther 2022; 14:125. [PMID: 36068621 PMCID: PMC9446839 DOI: 10.1186/s13195-022-01057-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Accepted: 07/29/2022] [Indexed: 11/10/2022]
Abstract
Abstract
Background
Older individuals with subjective cognitive decline (SCD) perceive that their cognition has declined but do not show objective impairment on neuropsychological tests. Individuals with SCD are at elevated risk of objective cognitive decline and incident dementia. Non-pharmacological interventions (including mindfulness-based and health self-management approaches) are a potential strategy to maintain or improve cognition in SCD, which may ultimately reduce dementia risk.
Methods
This study utilized data from the SCD-Well randomized controlled trial. One hundred forty-seven older adults with SCD (MAge = 72.7 years; 64% female) were recruited from memory clinics in four European countries and randomized to one of two group-based, 8-week interventions: a Caring Mindfulness-based Approach for Seniors (CMBAS) or a health self-management program (HSMP). Participants were assessed at baseline, post-intervention (week 8), and at 6-month follow-up (week 24) using a range of cognitive tests. From these tests, three composites were derived—an “abridged” Preclinical Alzheimer’s Cognitive Composite 5 (PACC5Abridged), an attention composite, and an executive function composite. Both per-protocol and intention-to-treat analyses were performed. Linear mixed models evaluated the change in outcomes between and within arms and adjusted for covariates and cognitive retest effects. Sensitivity models repeated the per-protocol analyses for participants who attended ≥ 4 intervention sessions.
Results
Across all cognitive composites, there were no significant time-by-trial arm interactions and no measurable cognitive retest effects; sensitivity analyses supported these results. Improvements, however, were observed within both trial arms on the PACC5Abridged from baseline to follow-up (Δ [95% confidence interval]: CMBAS = 0.34 [0.19, 0.48]; HSMP = 0.30 [0.15, 0.44]). There was weaker evidence of an improvement in attention but no effects on executive function.
Conclusions
Two non-pharmacological interventions conferred small, non-differing improvements to a global cognitive composite sensitive to amyloid-beta-related decline. There was weaker evidence of an effect on attention, and no evidence of an effect on executive function. Importantly, observed improvements were maintained beyond the end of the interventions. Improving cognition is an important step toward dementia prevention, and future research is needed to delineate the mechanisms of action of these interventions and to utilize clinical endpoints (i.e., progression to mild cognitive impairment or dementia).
Trial registration
ClinicalTrials.gov, NCT03005652.
Collapse
|
8
|
Akinci M, Sánchez-Benavides G, Brugulat-Serrat A, Peña-Gómez C, Palpatzis E, Shekari M, Deulofeu C, Fuentes-Julian S, Salvadó G, González-de-Echávarri JM, Suárez-Calvet M, Minguillón C, Fauria K, Molinuevo JL, Gispert JD, Grau-Rivera O, Arenaza-Urquijo EM, Beteta A, Cacciaglia R, Cañas A, Cumplido I, Dominguez R, Emilio M, Falcon C, Hernandez L, Huesa G, Huguet J, Marne P, Menchón T, Operto G, Polo A, Rodríguez-Fernández B, Pradas S, Sadeghi I, Soteras A, Stankeviciute L, Vilanova M, Vilor-Tejedor N. Subjective cognitive decline and anxious/depressive symptoms during the COVID-19 pandemic: what is the role of stress perception, stress resilience, and β-amyloid? Alzheimers Res Ther 2022; 14:126. [PMID: 36068641 PMCID: PMC9446623 DOI: 10.1186/s13195-022-01068-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Accepted: 08/28/2022] [Indexed: 11/10/2022]
Abstract
Abstract
Background
The COVID-19 pandemic may worsen the mental health of people reporting subjective cognitive decline (SCD) and therefore their clinical prognosis. We aimed to investigate the association between the intensity of SCD and anxious/depressive symptoms during confinement and the underlying mechanisms.
Methods
Two hundred fifty cognitively unimpaired participants completed the Hospital Anxiety and Depression Scale (HADS) and SCD-Questionnaire (SCD-Q) and underwent amyloid-β positron emission tomography imaging with [18F] flutemetamol (N = 205) on average 2.4 (± 0.8) years before the COVID-19 confinement. During the confinement, participants completed the HADS, Perceived Stress Scale (PSS), Brief Resilience Scale (BRS), and an ad hoc questionnaire on worries (access to primary products, self-protection materials, economic situation) and lifestyle changes (sleep duration, sleep quality, eating habits). We investigated stress-related measurements, worries, and lifestyle changes in relation to SCD. We then conducted an analysis of covariance to investigate the association of SCD-Q with HADS scores during the confinement while controlling for pre-confinement anxiety/depression scores and demographics. Furthermore, we introduced amyloid-β positivity, PSS, and BRS in the models and performed mediation analyses to explore the mechanisms explaining the association between SCD and anxiety/depression.
Results
In the whole sample, the average SCD-Q score was 4.1 (± 4.4); 70 (28%) participants were classified as SCD, and 26 (12.7%) were amyloid-β-positive. During the confinement, participants reporting SCD showed higher PSS (p = 0.035) but not BRS scores (p = 0.65) than those that did not report SCD. No differences in worries or lifestyle changes were observed. Higher SCD-Q scores showed an association with greater anxiety/depression scores irrespective of pre-confinement anxiety/depression levels (p = 0.002). This association was not significant after introducing amyloid-β positivity and stress-related variables in the model (p = 0.069). Amyloid-β positivity and PSS were associated with greater HADS irrespective of pre-confinement anxiety/depression scores (p = 0.023; p < 0.001). The association of SCD-Q with HADS was mediated by PSS (p = 0.01).
Conclusions
Higher intensity of SCD, amyloid-β positivity, and stress perception showed independent associations with anxious/depressive symptoms during the COVID-19 confinement irrespective of pre-confinement anxiety/depression levels. The association of SCD intensity with anxiety/depression was mediated by stress perception, suggesting stress regulation as a potential intervention to reduce affective symptomatology in the SCD population in the face of stressors.
Collapse
|
9
|
Cai ZZ, Lin R, Wang XX, Yan YJ, Li H. Effects of mindfulness in patients with mild cognitive impairment with insomnia: A double-blind randomized controlled trial. Geriatr Nurs 2022; 47:239-246. [PMID: 36027785 DOI: 10.1016/j.gerinurse.2022.08.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2022] [Revised: 07/30/2022] [Accepted: 08/01/2022] [Indexed: 11/19/2022]
Abstract
OBJECTIVE Current research on the effects of mindfulness therapy on MCI and insomnia has been inconsistent. It is still a hot topic of research and discussion. This study aimed to improve the sleep quality, cognition, and mental state of patients with mild cognitive impairment (MCI) with insomnia. METHODS A double-blind randomized controlled trial was conducted. Seventy-five patients who met the eligibility criteria were randomly assigned to the mindfulness (n = 38) or health education (n = 37) treatment group. The primary outcomes were sleep, measured by the Pittsburgh Sleep Quality Inventory, and cognition, measured by The Montreal Cognitive Assessment and Mini-Mental State Examination. Secondary outcomes included insomnia, measured by the Insomnia Severity Index, depression, anxiety, and perceived stress. EEG signals were collected at rest with eyes closed in the mindfulness state. The power spectrum was analyzed from these data. RESULTS Cognitive function and sleep quality were significantly improved in the mindfulness group (95% confidence interval 0.04 - 0.05, 0.03 - 0.04, -5.58 - -1.55, respectively). Anxiety and perceived stress scores were significantly lower than those in the control group (95% confidence interval 0.002 - 0.004, 0.009 - 0.013, respectively). The power spectrum differences in δ, θ, β, and γ bands were significant between the rest and mindfulness states (P < .05). Good safety was achieved in both groups with no deaths or serious adverse events. CONCLUSION Mindfulness improved sleep quality, cognitive function, and mentality of patients. Mindfulness practice caused deep relaxation in the brain and changes in electrical frequency bands associated with attention and cognitive tasks. Mindfulness learning can be performed successfully for individuals with MCI. Additionally, it is suitable for adoption in nursing homes.
Collapse
Affiliation(s)
- Zhen-Zhen Cai
- The School of Nursing, Fujian Medical University, Fuzhou, China
| | - Rong Lin
- Post-Doctoral Research Center, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China
| | - Xiao-Xia Wang
- The School of Nursing, Fujian Medical University, Fuzhou, China
| | - Yuan-Jiao Yan
- The School of Nursing, Fujian Medical University, Fuzhou, China
| | - Hong Li
- School of Nursing, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China; Department of Nursing, Fujian Provincial Hospital, Fuzhou, China.
| |
Collapse
|
10
|
Rostamzadeh A, Kahlert A, Kalthegener F, Jessen F. Psychotherapeutic interventions in individuals at risk for Alzheimer's dementia: a systematic review. Alzheimers Res Ther 2022; 14:18. [PMID: 35101105 PMCID: PMC8802419 DOI: 10.1186/s13195-021-00956-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Accepted: 12/23/2021] [Indexed: 06/14/2023]
Abstract
BACKGROUND Expanding technologies of early detection of Alzheimer's disease allow to identify individuals at risk of dementia in early and asymptomatic disease stages. Neuropsychiatric symptoms, such as anxiety and depression, are common in the course of AD and may be clinically observed many years before the onset of significant cognitive symptoms. To date, therapeutic interventions for AD focus on pharmacological and life style modification-based strategies. However, despite good evidence for psychotherapy in late-life depression, evidence for such therapeutic approaches to improve cognitive and emotional well-being and thereby reduce psychological risk factors in the course of AD are sparse. METHODS A systematic review was conducted in PUBMED, PsycINFO, Web of Science, and Clinical Trials to summarize the state of evidence on psychotherapeutic and psychoeducational interventions for individuals at risk for Alzheimer's dementia. Eligible articles needed to apply a manualized and standardized psychotherapeutic or psychoeducational content administered by trained professionals for individuals with subjective cognitive decline or mild cognitive impairment and measure mental health, quality of life or well-being. RESULTS The literature search yielded 32 studies that were included in this narrative summary. The data illustrates heterogeneous therapeutic approaches with mostly small sample sizes and short follow-up monitoring. Strength of evidence from randomized-controlled studies for interventions that may improve mood and well-being is scarce. Qualitative data suggests positive impact on cognitive restructuring, and disease acceptance, including positive effects on quality of life. Specific therapeutic determinants of efficacy have not been identified to date. CONCLUSIONS This review underlines the need of specific psychotherapeutic and psychoeducational approaches for individuals at risk of Alzheimer's dementia, particularly in terms of an early intervention aiming at improving mental health and well-being. One challenge is the modification of psychotherapeutic techniques according to the different stages of cognitive decline in the course of AD, which is needed to be sensitive to the individual needs.
Collapse
Affiliation(s)
- Ayda Rostamzadeh
- Department of Psychiatry and Psychotherapy, University of Cologne, Medical Faculty, 50937, Cologne, Germany.
| | - Anna Kahlert
- Institute for Psychology, Rheinisch Westfälische Hochschule Aachen, Philosophical Faculty, 52056, Aachen, Germany
| | - Franziska Kalthegener
- Department of Psychiatry and Psychotherapy, University of Cologne, Medical Faculty, 50937, Cologne, Germany
| | - Frank Jessen
- Department of Psychiatry and Psychotherapy, University of Cologne, Medical Faculty, 50937, Cologne, Germany
- German Center for Neurodegenerative Diseases (DZNE), Venusberg Campus 1, Gebäude 99, 53127, Bonn, Germany
- Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, 50924, Cologne, Germany
| |
Collapse
|
11
|
Strikwerda-Brown C, Ozlen H, Pichet Binette A, Chapleau M, Marchant NL, Breitner JC, Villeneuve S. Trait Mindfulness Is Associated With Less Amyloid, Tau, and Cognitive Decline in Individuals at Risk for Alzheimer's Disease. BIOLOGICAL PSYCHIATRY GLOBAL OPEN SCIENCE 2022; 3:130-138. [PMID: 36712573 PMCID: PMC9874144 DOI: 10.1016/j.bpsgos.2022.01.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2021] [Revised: 01/06/2022] [Accepted: 01/06/2022] [Indexed: 02/01/2023] Open
Abstract
Background Mindfulness, defined as nonjudgmental awareness of the present moment, has been associated with an array of mental and physical health benefits. Mindfulness may also represent a protective factor for Alzheimer's disease (AD). Here, we tested the potential protective effect of trait mindfulness on cognitive decline and AD pathology in older adults at risk for AD dementia. Methods Measures of trait mindfulness, longitudinal cognitive assessments, and amyloid-β (Aβ) and tau positron emission tomography scans were collected in 261 nondemented older adults with a family history of AD dementia from the PREVENT-AD (Pre-symptomatic Evaluation of Experimental or Novel Treatments for AD) observational cohort study. Multivariate partial least squares analyses were used to examine relationships between combinations of different facets of trait mindfulness and 1) cognitive decline, 2) Aβ, and 3) tau. Results Higher levels of mindful nonjudgment, describing, and nonreactivity were associated with less cognitive decline in attention, global cognition, and immediate and delayed memory. Higher levels of mindful nonjudgment and nonreactivity were related to less Aβ positron emission tomography signal in bilateral medial and lateral temporoparietal and frontal regions. Higher levels of mindful acting with awareness, describing, nonjudgment, and nonreactivity were associated with less tau positron emission tomography signal in bilateral medial and lateral temporal regions. Conclusions Trait mindfulness was associated with less cognitive decline and less Aβ and tau in the brain in older adults at risk for AD dementia. Longitudinal studies examining the temporal relationship between trait mindfulness and AD markers, along with mindfulness intervention studies, will be important for further clarifying the potential protective benefits of mindfulness on AD risk.
Collapse
Affiliation(s)
- Cherie Strikwerda-Brown
- Centre for Studies on the Prevention of Alzheimer’s Disease, Douglas Mental Health University Institute, Montreal, Quebec, Canada,Department of Psychiatry, McGill University, Montreal, Quebec, Canada,Cherie Strikwerda-Brown, Ph.D.
| | - Hazal Ozlen
- Centre for Studies on the Prevention of Alzheimer’s Disease, Douglas Mental Health University Institute, Montreal, Quebec, Canada
| | - Alexa Pichet Binette
- Centre for Studies on the Prevention of Alzheimer’s Disease, Douglas Mental Health University Institute, Montreal, Quebec, Canada,Department of Psychiatry, McGill University, Montreal, Quebec, Canada,McGill Centre for Integrative Neuroscience, McGill University, Montreal, Quebec, Canada
| | - Marianne Chapleau
- Centre for Studies on the Prevention of Alzheimer’s Disease, Douglas Mental Health University Institute, Montreal, Quebec, Canada
| | - Natalie L. Marchant
- Division of Psychiatry, Faculty of Brain Sciences, University College London, London, United Kingdom
| | - John C.S. Breitner
- Centre for Studies on the Prevention of Alzheimer’s Disease, Douglas Mental Health University Institute, Montreal, Quebec, Canada,Department of Psychiatry, McGill University, Montreal, Quebec, Canada
| | - Sylvia Villeneuve
- Centre for Studies on the Prevention of Alzheimer’s Disease, Douglas Mental Health University Institute, Montreal, Quebec, Canada,Department of Psychiatry, McGill University, Montreal, Quebec, Canada,McGill Centre for Integrative Neuroscience, McGill University, Montreal, Quebec, Canada,Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada,McConnell Brain Imaging Centre, Montreal Neurological Institute, Montreal, Quebec, Canada,Address correspondence to Sylvia Villeneuve, Ph.D.
| |
Collapse
|
12
|
Study of the effects of mindfulness training on quality of life of patients with Alzheimer's disease and their caregivers (Dyad Mindfulness Project). Aging Clin Exp Res 2022; 34:65-71. [PMID: 34213748 DOI: 10.1007/s40520-021-01907-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2021] [Accepted: 06/04/2021] [Indexed: 10/20/2022]
Abstract
BACKGROUND The training of mindfulness enhances the emotive and cognitive equilibrium and well-being in older adults. So some authors hypothesize it is an appropriate approach to cultivating these benefits and a good quality of life in Alzheimer's patients (AD-P) at early stage and in their caregivers (Cg) (Dyad). AIM Our main hypothesis is that AD-P and Cg who completed the program of Mindfulness-Based Interventions (MBIs) training would experience improvements in well-being and mood and cognitive performance (AD-P: attention and memory). METHODS The perspective randomized controlled will enroll the Dyad of 80 Alzheimer's patients (age ≥ 60) and 80 caregivers (age > 18) who will be randomly assigned to 6 months MBI training in groups and to control group study. All outcome will be analyzed before intervention (baseline), after follow-up 1 (at the end of treatment), after 6 months (follow-up 2) and after 1 year (follow-up 3) from the end of treatment. DISCUSSION AD-P-expected outcomes: (a) improvement of the quality of life (QoL-AD); (b) decrease of depression (BDI); (c) improvement of spiritual well-being (Facit SWB Index); (d) improvement of attention and good cognitive performance Rey Memory Test (MFIT); (e) decrease of neuropsychiatric symptoms. (NPI)-Cg-expected outcomes: (a) improvement of the quality of life (SF36); (b) decrease of the care burden (CBI); (c) decrease of depression (BDI); (d) improvement of self-awareness (FFMQ); (e) increase in spiritual-well-being (Facit SWB). CONCLUSIONS This study could provide a clues on multidisciplinary interventions as secondary prevention of Alzheimer's dementia and on stress reduction in family caregivers.
Collapse
|
13
|
Lutz A, Chételat G, Collette F, Klimecki OM, Marchant NL, Gonneaud J. The protective effect of mindfulness and compassion meditation practices on ageing: Hypotheses, models and experimental implementation. Ageing Res Rev 2021; 72:101495. [PMID: 34718153 DOI: 10.1016/j.arr.2021.101495] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Revised: 09/09/2021] [Accepted: 10/18/2021] [Indexed: 10/20/2022]
Abstract
Alzheimer's disease (AD) represents a major health and societal issue; there is no treatment to date and the pathophysiological mechanisms underlying this disease are not well understood. Yet, there is hope that AD risk factors and thus the number of AD cases can be significantly reduced by prevention measures based on lifestyle modifications as targeted by non-pharmacological preventive interventions. So far, these interventions have rarely targeted the psycho-affective risk factors related to depression, stress, anxiety, and feeling of loneliness, which are all prevalent in ageing. This paper presents the hypothesis that the regular practice of mindfulness meditation (MM) and loving-kindness and compassion meditation (LKCM) in the ageing population constitutes a lifestyle that is protective against AD. In this model, these practices can promote cognition, mental health, and well-being by strengthening attention control, metacognitive monitoring, emotion regulation and pro-social capacities. Training these capacities could reduce the risk of AD by upregulating beneficial age-related factors such as cognitive reserve, and down-regulating detrimental age-related factors, such as stress, or depression. As an illustration, we present the Medit-Ageing study (public name Silver Santé Study), an on-going European project that assesses the impact and mechanisms of non-pharmacological interventions including meditation, in the ageing population.
Collapse
|
14
|
Ourry V, Marchant NL, Schild AK, Coll-Padros N, Klimecki OM, Krolak-Salmon P, Goldet K, Reyrolle L, Bachelet R, Sannemann L, Meiberth D, Demnitz-King H, Whitfield T, Botton M, Lebahar J, Gonneaud J, de Flores R, Molinuevo JL, Jessen F, Vivien D, de la Sayette V, Valenzuela MJ, Rauchs G, Wirth M, Chételat G, Arenaza-Urquijo EM. Harmonisation and Between-Country Differences of the Lifetime of Experiences Questionnaire in Older Adults. Front Aging Neurosci 2021; 13:740005. [PMID: 34720992 PMCID: PMC8551756 DOI: 10.3389/fnagi.2021.740005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2021] [Accepted: 09/13/2021] [Indexed: 11/13/2022] Open
Abstract
Background: The Lifetime of Experiences Questionnaire (LEQ) assesses complex mental activity across the life-course and has been associated with brain and cognitive health. The different education systems and occupation classifications across countries represent a challenge for international comparisons. The objectives of this study were four-fold: to adapt and harmonise the LEQ across four European countries, assess its validity across countries, explore its association with brain and cognition and begin to investigate between-country differences in life-course mental activities. Method: The LEQ was administered to 359 cognitively unimpaired older adults (mean age and education: 71.2, 13.2 years) from IMAP and EU-funded Medit-Ageing projects. Education systems, classification of occupations and scoring guidelines were adapted to allow comparisons between France, Germany, Spain and United Kingdom. We assessed the LEQ's (i) concurrent validity with a similar instrument (cognitive activities questionnaire - CAQ) and its structural validity by testing the factors' structure across countries, (ii) we investigated its association with cognition and neuroimaging, and (iii) compared its scores between countries. Results: The LEQ showed moderate to strong positive associations with the CAQ and revealed a stable multidimensional structure across countries that was similar to the original LEQ. The LEQ was positively associated with global cognition. Between-country differences were observed in leisure activities across the life-course. Conclusions: The LEQ is a promising tool for assessing the multidimensional construct of cognitive reserve and can be used to measure socio-behavioural determinants of cognitive reserve in older adults across countries. Longitudinal studies are warranted to test further its clinical utility.
Collapse
Affiliation(s)
- Valentin Ourry
- Normandie University, UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging of Neurological Disorders", Institut Blood and Brain @ Caen-Normandie, Caen, France.,Normandie University, UNICAEN, PSL Université, EPHE, INSERM, U1077, CHU de Caen, GIP Cyceron, NIMH, Caen, France
| | - Natalie L Marchant
- Division of Psychiatry, University College London, London, United Kingdom
| | - Ann-Katrin Schild
- Department of Psychiatry, Medical Faculty, University of Cologne, Cologne, Germany
| | - Nina Coll-Padros
- Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain
| | - Olga M Klimecki
- Clinical Psychology and Behavioural Neuroscience, Technische Universität Dresden, Dresden, Germany
| | - Pierre Krolak-Salmon
- Clinical and Research Memory Center, Hospices Civils de Lyon, Université de Lyon, INSERM, Lyon, France
| | - Karine Goldet
- Hospices Civils de Lyon, Institut du Vieillissement, CRC Vieillissement-Cerveau-Fragilite, Lyon, France
| | - Leslie Reyrolle
- Hospices Civils de Lyon, Institut du Vieillissement, CRC Vieillissement-Cerveau-Fragilite, Lyon, France
| | - Romain Bachelet
- Hospices Civils de Lyon, Institut du Vieillissement, CRC Vieillissement-Cerveau-Fragilite, Lyon, France
| | - Lena Sannemann
- Department of Psychiatry, Medical Faculty, University of Cologne, Cologne, Germany
| | - Dix Meiberth
- Department of Psychiatry, Medical Faculty, University of Cologne, Cologne, Germany
| | | | - Tim Whitfield
- Division of Psychiatry, University College London, London, United Kingdom
| | - Maëlle Botton
- Normandie University, UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging of Neurological Disorders", Institut Blood and Brain @ Caen-Normandie, Caen, France
| | - Julie Lebahar
- Normandie University, UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging of Neurological Disorders", Institut Blood and Brain @ Caen-Normandie, Caen, France
| | - Julie Gonneaud
- Normandie University, UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging of Neurological Disorders", Institut Blood and Brain @ Caen-Normandie, Caen, France
| | - Robin de Flores
- Normandie University, UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging of Neurological Disorders", Institut Blood and Brain @ Caen-Normandie, Caen, France
| | - José Luis Molinuevo
- Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain
| | - Frank Jessen
- Department of Psychiatry, Medical Faculty, University of Cologne, Cologne, Germany
| | - Denis Vivien
- Normandie University, UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging of Neurological Disorders", Institut Blood and Brain @ Caen-Normandie, Caen, France.,Département de Recherche Clinique, CHU Caen-Normandie, Caen, France
| | - Vincent de la Sayette
- Normandie University, UNICAEN, PSL Université, EPHE, INSERM, U1077, CHU de Caen, GIP Cyceron, NIMH, Caen, France.,Service de Neurologie, CHU de Caen, Caen, France
| | - Michael J Valenzuela
- School of Psychiatry, University of New South Wales, Sydney, NSW, Australia.,Skin2Neuron Pty Ltd., Sydney, NSW, Australia
| | - Géraldine Rauchs
- Normandie University, UNICAEN, PSL Université, EPHE, INSERM, U1077, CHU de Caen, GIP Cyceron, NIMH, Caen, France
| | - Miranka Wirth
- German Centre for Neurodegenerative Diseases (DZNE), Dresden, Germany
| | - Gaël Chételat
- Normandie University, UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging of Neurological Disorders", Institut Blood and Brain @ Caen-Normandie, Caen, France
| | - Eider M Arenaza-Urquijo
- Normandie University, UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging of Neurological Disorders", Institut Blood and Brain @ Caen-Normandie, Caen, France.,Barcelonabeta Brain Research Center, Fundación Pasqual Maragall, Barcelona, Spain
| | | |
Collapse
|
15
|
Marchant NL, Barnhofer T, Coueron R, Wirth M, Lutz A, Arenaza-Urquijo EM, Collette F, Poisnel G, Demnitz-King H, Schild AK, Coll-Padros N, Delphin-Combe F, Whitfield T, Schlosser M, Gonneaud J, Asselineau J, Walker Z, Krolak-Salmon P, Molinuevo JL, Frison E, Chételat G, Jessen F, Klimecki OM. Effects of a Mindfulness-Based Intervention versus Health Self-Management on Subclinical Anxiety in Older Adults with Subjective Cognitive Decline: The SCD-Well Randomized Superiority Trial. PSYCHOTHERAPY AND PSYCHOSOMATICS 2021; 90:341-350. [PMID: 33873195 DOI: 10.1159/000515669] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/15/2020] [Accepted: 03/02/2021] [Indexed: 11/19/2022]
Abstract
INTRODUCTION Older adults experiencing subjective cognitive decline (SCD) have a heightened risk of developing dementia and frequently experience subclinical anxiety, which is itself associated with dementia risk. OBJECTIVE To understand whether subclinical anxiety symptoms in SCD can be reduced through behavioral interventions. METHODS SCD-Well is a randomized controlled trial designed to determine whether an 8-week mindfulness-based intervention (caring mindfulness-based approach for seniors; CMBAS) is superior to a structurally matched health self-management program (HSMP) in reducing subclinical anxiety. Participants were recruited from memory clinics at 4 European sites. The primary outcome was change in anxiety symptoms (trait subscale of the State-Trait Anxiety Inventory; trait-STAI) from pre- to postintervention. Secondary outcomes included a change in state anxiety and depression symptoms postintervention and 6 months postrandomization (follow-up). RESULTS One hundred forty-seven participants (mean [SD] age: 72.7 [6.9] years; 64.6% women; CMBAS, n = 73; HSMP, n = 74) were included in the intention-to-treat analysis. There was no difference in trait-STAI between groups postintervention (adjusted change difference: -1.25 points; 95% CI -4.76 to 2.25) or at follow-up (adjusted change difference: -0.43 points; 95% CI -2.92 to 2.07). Trait-STAI decreased postintervention in both groups (CMBAS: -3.43 points; 95% CI -5.27 to -1.59; HSMP: -2.29 points; 95% CI -4.14 to -0.44) and reductions were maintained at follow-up. No between-group differences were observed for change in state anxiety or depression symptoms. CONCLUSIONS A time-limited mindfulness intervention is not superior to health self-management in reducing subclinical anxiety symptoms in SCD. The sustained reduction observed across both groups suggests that subclinical anxiety symptoms in SCD are modifiable. ClinicalTrials.gov identifier: NCT03005652.
Collapse
Affiliation(s)
- Natalie L Marchant
- Division of Psychiatry, University College London, London, United Kingdom
| | - Thorsten Barnhofer
- Mood Disorders Centre, University of Exeter, Exeter, United Kingdom.,School of Psychology, University of Surrey, Guildford, United Kingdom
| | - Roxane Coueron
- EUCLID/F-CRIN Clinical Trials Platform, University of Bordeaux, Inserm, Bordeaux Population Health Center, Bordeaux, France.,CHU Bordeaux, Service d' Information Médicale, Bordeaux, France
| | - Miranka Wirth
- Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humbold-Universität zu Berlin and Berlin Institute of Health, NeuroCure Clinical Research Center, Berlin, Germany.,German Center for Neurodegenerative Diseases (DZNE), Dresden, Germany
| | - Antoine Lutz
- Lyon Neuroscience Research Center Inserm U1028, CNRS UMR5292, Lyon 1 University, Lyon, France
| | - Eider M Arenaza-Urquijo
- Inserm, Inserm UMR-S U1237, Université de Caen-Normandie, GIP Cyceron, Caen, France.,Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.,Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.,Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBER FES), Madrid, Spain
| | - Fabienne Collette
- GIGA-CRC In Vivo Imaging, Université de Liège, National Fund for Scientific Research (F.R.S.-FNRS), Liège, Belgium
| | - Géraldine Poisnel
- Inserm, Inserm UMR-S U1237, Université de Caen-Normandie, GIP Cyceron, Caen, France
| | | | - Ann-Katrin Schild
- Department of Psychiatry, Medical Faculty, University of Cologne, Cologne, Germany
| | - Nina Coll-Padros
- Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain
| | - Floriane Delphin-Combe
- Hospices Civils de Lyon, Institut du Vieillissement, CRC Vieillissement-Cerveau-Fragilité, Lyon, France
| | - Tim Whitfield
- Division of Psychiatry, University College London, London, United Kingdom
| | - Marco Schlosser
- Division of Psychiatry, University College London, London, United Kingdom
| | - Julie Gonneaud
- Inserm, Inserm UMR-S U1237, Université de Caen-Normandie, GIP Cyceron, Caen, France
| | - Julien Asselineau
- EUCLID/F-CRIN Clinical Trials Platform, University of Bordeaux, Inserm, Bordeaux Population Health Center, Bordeaux, France.,CHU Bordeaux, Service d' Information Médicale, Bordeaux, France
| | - Zuzana Walker
- Division of Psychiatry, University College London, London, United Kingdom.,Essex Partnership University NHS Foundation Trust, Essex, United Kingdom
| | - Pierre Krolak-Salmon
- Hospices Civils de Lyon, Institut du Vieillissement, CRC Vieillissement-Cerveau-Fragilité, Lyon, France
| | - José Luis Molinuevo
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.,Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.,Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBER FES), Madrid, Spain.,Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain
| | - Eric Frison
- EUCLID/F-CRIN Clinical Trials Platform, University of Bordeaux, Inserm, Bordeaux Population Health Center, Bordeaux, France.,CHU Bordeaux, Service d' Information Médicale, Bordeaux, France
| | - Gael Chételat
- Inserm, Inserm UMR-S U1237, Université de Caen-Normandie, GIP Cyceron, Caen, France
| | - Frank Jessen
- Department of Psychiatry, Medical Faculty, University of Cologne, Cologne, Germany.,German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.,Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany
| | - Olga M Klimecki
- Swiss Center for Affective Sciences, Department of Medicine and Department of Psychology, Department of Political Science and International Relations, University of Geneva, Geneva, Switzerland.,Clinical Psychology and Behavioral Neuroscience, Faculty of Psychology, Technische Universität Dresden, Dresden, Germany
| | | |
Collapse
|
16
|
The psychometric properties of the compassionate love scale and the validation of the English and German 7-item compassion for others scale (COS-7). CURRENT PSYCHOLOGY 2021. [DOI: 10.1007/s12144-020-01344-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
17
|
Schlosser M, Demnitz-King H, Whitfield T, Wirth M, Marchant NL. Repetitive negative thinking is associated with subjective cognitive decline in older adults: a cross-sectional study. BMC Psychiatry 2020; 20:500. [PMID: 33036587 PMCID: PMC7547434 DOI: 10.1186/s12888-020-02884-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/06/2020] [Accepted: 09/19/2020] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND In the absence of a cure or effective treatment for dementia, attention has shifted towards identifying risk factors for prevention. Subjective Cognitive Decline (SCD) describes self-perceived worsening of cognition despite unimpaired performance on neuropsychological tests. SCD has been associated with an increased dementia risk and steeper memory decline. Repetitive negative thinking (RNT) is a transdiagnostic process that manifests across several mental health disorders associated with increased vulnerability to dementia. RNT has thus been proposed as a candidate marker of risk for dementia and, relatedly, could contribute to the manifestation of SCD. We aimed to investigate the relationship between SCD and RNT alongside other proposed psychological risk/protective factors for dementia and cognitive decline. METHODS In a cross-sectional online survey, 491 older adults (mean = 64.9 years, SD = 4.2; 63.1% female) completed measures of RNT, personality traits, purpose in life, worry, rumination, and meditation practice. SCD was assessed continuously via self-perceived cognitive function (Neuro-QoL) and categorically via endorsement (yes/no) of memory complaints. Regression models, using a stepwise backwards elimination, were built to assess associations between SCD, demographics, and all risk/protective factors. RESULTS A total of 24.2% of participants reported memory complaints. In the final prediction models, RNT was the only psychological variable associated with lower self-perceived cognitive function and with a higher likelihood of memory complaints. CONCLUSIONS This study empirically corroborates the theoretical relationship between SCD and RNT. Longitudinal studies are needed to establish whether RNT is a prodromal symptom or an independent risk factor, and whether RNT can be a promising construct for future research on SCD and dementia risk.
Collapse
Affiliation(s)
- Marco Schlosser
- Division of Psychiatry, Faculty of Brain Sciences, University College London, 6th Floor, Wing A, Maple House, 149 Tottenham Court Road, London, W1T 7NF, UK. .,Department of Psychology, Faculty of Psychology and Educational Sciences, University of Geneva, Geneva, Switzerland.
| | - Harriet Demnitz-King
- grid.83440.3b0000000121901201Division of Psychiatry, Faculty of Brain Sciences, University College London, 6th Floor, Wing A, Maple House, 149 Tottenham Court Road, London, W1T 7NF UK
| | - Tim Whitfield
- grid.83440.3b0000000121901201Division of Psychiatry, Faculty of Brain Sciences, University College London, 6th Floor, Wing A, Maple House, 149 Tottenham Court Road, London, W1T 7NF UK
| | - Miranka Wirth
- German Center for Neurodegenerative Diseases (DZNE) Dresden, Dresden, Germany
| | - Natalie L. Marchant
- grid.83440.3b0000000121901201Division of Psychiatry, Faculty of Brain Sciences, University College London, 6th Floor, Wing A, Maple House, 149 Tottenham Court Road, London, W1T 7NF UK
| |
Collapse
|
18
|
Marchant NL, Lovland LR, Jones R, Pichet Binette A, Gonneaud J, Arenaza‐Urquijo EM, Chételat G, Villeneuve S. Repetitive negative thinking is associated with amyloid, tau, and cognitive decline. Alzheimers Dement 2020; 16:1054-1064. [DOI: 10.1002/alz.12116] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2020] [Revised: 03/25/2020] [Accepted: 04/18/2020] [Indexed: 01/05/2023]
Affiliation(s)
| | - Lise R. Lovland
- Division of PsychiatryUniversity College London London United Kingdom
| | - Rebecca Jones
- Division of PsychiatryUniversity College London London United Kingdom
| | - Alexa Pichet Binette
- Studies on Prevention of Alzheimer's Disease (StOP‐AD) CentreDouglas Mental Health University Institute Montreal Quebec Canada
- McGill Integrated Program in NeuroscienceMcGill University Montreal Quebec Canada
| | - Julie Gonneaud
- Studies on Prevention of Alzheimer's Disease (StOP‐AD) CentreDouglas Mental Health University Institute Montreal Quebec Canada
- McGill Integrated Program in NeuroscienceMcGill University Montreal Quebec Canada
| | - Eider M. Arenaza‐Urquijo
- Normandie Univ, UNICAEN, INSERM, U1237PhIND “Physiopathology and Imaging of Neurological Disorders”, Cyceron Caen 14000 France
- Barcelonaβeta Brain Research CenterPasqual Maragall Foundation Barcelona Spain
| | - Gael Chételat
- Normandie Univ, UNICAEN, INSERM, U1237PhIND “Physiopathology and Imaging of Neurological Disorders”, Cyceron Caen 14000 France
| | - Sylvia Villeneuve
- Studies on Prevention of Alzheimer's Disease (StOP‐AD) CentreDouglas Mental Health University Institute Montreal Quebec Canada
- McGill Integrated Program in NeuroscienceMcGill University Montreal Quebec Canada
| | | |
Collapse
|
19
|
Understanding mindfulness, one moment at a time: an introduction to the special issue. Curr Opin Psychol 2019; 28:vi-x. [PMID: 31451390 DOI: 10.1016/j.copsyc.2019.08.001] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
20
|
Abstract
Empathy and empathy-related processes, such as compassion and personal distress, are recognized to play a key role in social relations. This review examines the role of empathy in interpersonal and intergroup relations, including intractable conflicts. Despite the limitations of empathy, there is growing evidence that empathy and compassion are associated with more prosocial behavior in interpersonal relations. Furthermore, empathy and compassion have been associated with more favorable attitudes and higher readiness for reconciliation across a range of intergroup settings. This review ends by summarizing recent evidence for the beneficial effects of compassion training on interpersonal and intergroup relations and by outlining new avenues for future research on how compassion training could reduce intergroup conflicts.
Collapse
Affiliation(s)
- Olga M. Klimecki
- Swiss Centre for Affective Sciences, University of Geneva, Switzerland
- Department of Medicine, University of Geneva, Switzerland
| |
Collapse
|
21
|
Effects of spermidine supplementation on cognition and biomarkers in older adults with subjective cognitive decline (SmartAge)-study protocol for a randomized controlled trial. ALZHEIMERS RESEARCH & THERAPY 2019; 11:36. [PMID: 31039826 PMCID: PMC6492385 DOI: 10.1186/s13195-019-0484-1] [Citation(s) in RCA: 61] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/01/2018] [Accepted: 03/20/2019] [Indexed: 12/18/2022]
Abstract
Background Given the global increase in the aging population and age-related diseases, the promotion of healthy aging is one of the most crucial public health issues. This trial aims to contribute to the establishment of effective approaches to promote cognitive and brain health in older individuals with subjective cognitive decline (SCD). Presence of SCD is known to increase the risk of objective cognitive decline and progression to dementia due to Alzheimer’s disease. Therefore, it is our primary goal to determine whether spermidine supplementation has a positive impact on memory performance in this at-risk group, as compared with placebo. The secondary goal is to examine the effects of spermidine intake on other neuropsychological, behavioral, and physiological parameters. Methods The SmartAge trial is a monocentric, randomized, double-blind, placebo-controlled phase IIb trial. The study will investigate 12 months of intervention with spermidine-based nutritional supplementation (target intervention) compared with 12 months of placebo intake (control intervention). We plan to recruit 100 cognitively normal older individuals with SCD from memory clinics, neurologists and general practitioners in private practice, and the general population. Participants will be allocated to one of the two study arms using blockwise randomization stratified by age and sex with a 1:1 allocation ratio. The primary outcome is the change in memory performance between baseline and post-intervention visits (12 months after baseline). Secondary outcomes include the change in memory performance from baseline to follow-up assessment (18 months after baseline), as well as changes in neurocognitive, behavioral, and physiological parameters (including blood and neuroimaging biomarkers), assessed at baseline and post-intervention. Discussion The SmartAge trial aims to provide evidence of the impact of spermidine supplementation on memory performance in older individuals with SCD. In addition, we will identify possible neurophysiological mechanisms of action underlying the anticipated cognitive benefits. Overall, this trial will contribute to the establishment of nutrition intervention in the prevention of Alzheimer’s disease. Trial registration ClinicalTrials.gov, NCT03094546. Registered 29 March 2017—retrospectively registered. Protocol version Based on EA1/250/16 version 1.5
Collapse
|
22
|
Klimecki O, Marchant NL, Lutz A, Poisnel G, Chételat G, Collette F. The impact of meditation on healthy ageing - the current state of knowledge and a roadmap to future directions. Curr Opin Psychol 2019; 28:223-228. [PMID: 30798104 DOI: 10.1016/j.copsyc.2019.01.006] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2018] [Revised: 01/05/2019] [Accepted: 01/13/2019] [Indexed: 12/16/2022]
Abstract
There is increasing evidence that meditation-based training promotes healthy ageing across many dimensions. This review summarizes the existing knowledge on the effects of meditation training on healthy ageing in the domains of emotions, cognition (with a special emphasis on attentional processes), and the preservation of related brain structures. Although evidence so far is promising, more rigorous randomized controlled studies with active control groups and long-term follow-up in older people are needed. We outline how these challenges can be addressed in future studies using the example of an ongoing project, Medit-Ageing (public name: Silver Santé Study), including two independent randomized controlled trials (RCT) as well as one cross-sectional study with meditation experts.
Collapse
Affiliation(s)
- Olga Klimecki
- Swiss Center for Affective Sciences, Department of Medicine, University of Geneva, Geneva, Switzerland.
| | - Natalie L Marchant
- Division of Psychiatry, University College London, London, United Kingdom
| | - Antoine Lutz
- Lyon Neuroscience Research Center, INSERM U1028, CNRS UMR5292, Lyon University, Lyon, France
| | - Géraldine Poisnel
- Université Normandie, Inserm, Université de Caen-Normandie, Inserm UMR-S U1237, GIP Cyceron, Caen, France
| | - Gaël Chételat
- Université Normandie, Inserm, Université de Caen-Normandie, Inserm UMR-S U1237, GIP Cyceron, Caen, France
| | - Fabienne Collette
- GIGA-CRC In Vivo Imaging and Psychology and Cognitive Neuroscience Research Unit, Liège University, Belgium
| |
Collapse
|